Results 161 to 170 of about 4,245 (206)
Peptide Receptor Radionuclide Therapy [PDF]
Journal of Clinical Endocrinology and Metabolism, 2022 The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to
Johannes Hofland +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Clinical Oncology, 2021
362 Background: 177Lu-dotatate PRRT is indicated in well-differentiated, SSTR+ small bowel NETs. These tumors often metastasize to mesenteric lymph nodes and produce a desmoplastic reaction, consisting of tumor cells mixed with fibrotic tissue. We hypothesized that in patients treated with 177Lu-dotatate, mesenteric tumors would remain stable even as
Eleonora Pelle +4 more
openaire +1 more source
362 Background: 177Lu-dotatate PRRT is indicated in well-differentiated, SSTR+ small bowel NETs. These tumors often metastasize to mesenteric lymph nodes and produce a desmoplastic reaction, consisting of tumor cells mixed with fibrotic tissue. We hypothesized that in patients treated with 177Lu-dotatate, mesenteric tumors would remain stable even as
Eleonora Pelle +4 more
openaire +1 more source
Cancer Biotherapy and Radiopharmaceuticals, 2009 Purpose: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity.
Alberto Agazzi +2 more
exaly +2 more sources
Hormone and Metabolic Research, 2012
Paragangliomas (PGLs) are neuroendocrine tum-ors that arise embryologically from the neural crest. Sympathetic PGLs can be located in the thoracic-abdominal region while parasympathetic PGLs are mainly situated in the head and neck region. Most PGLs are sporadic, but in 30% of cases they are hereditary (associated with mutations of SDHB, SDHC, SDHD ...
Zovato, S. +11 more
openaire +3 more sources
Paragangliomas (PGLs) are neuroendocrine tum-ors that arise embryologically from the neural crest. Sympathetic PGLs can be located in the thoracic-abdominal region while parasympathetic PGLs are mainly situated in the head and neck region. Most PGLs are sporadic, but in 30% of cases they are hereditary (associated with mutations of SDHB, SDHC, SDHD ...
Zovato, S. +11 more
openaire +3 more sources
Journal of Clinical Oncology, 2020
623 Background: Neuroendocrine tumors (NETs) are rare but increasing in incidence. The only curative treatment is surgery, which in many cases is not an option due to metastatic disease at diagnosis. The NETTER-1 study showed high efficacy and low toxicity of peptide receptor radionuclide therapy (PRRT) for midgut NETs.
Heying Duan +10 more
openaire +1 more source
623 Background: Neuroendocrine tumors (NETs) are rare but increasing in incidence. The only curative treatment is surgery, which in many cases is not an option due to metastatic disease at diagnosis. The NETTER-1 study showed high efficacy and low toxicity of peptide receptor radionuclide therapy (PRRT) for midgut NETs.
Heying Duan +10 more
openaire +1 more source
Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT).
Hellenic journal of nuclear medicine, 2016Neuroendocrine tumors (neuroendocrine tumors-NET) are a heterogeneous group of neoplasms with a common embryological origin and diverse biological behavior, derived from cells of the neuroendocrine system, the system APUD (amine precursor uptake and decarboxylation).
Dimitris G, Papamichail +2 more
openaire +3 more sources
Journal of Clinical Oncology, 2020
e16701 Background: PRRT received FDA approval in 2018 for treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) based on NETTER-1 trial data that included only small bowel grade 1 and 2 neuroendocrine tumors.
Justin Chau +5 more
openaire +1 more source
e16701 Background: PRRT received FDA approval in 2018 for treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) based on NETTER-1 trial data that included only small bowel grade 1 and 2 neuroendocrine tumors.
Justin Chau +5 more
openaire +1 more source
Receptor-Targeted Radionuclide Imaging (RTRI) and Peptide Receptor Radionuclide Therapy (PRRT)
2019Increased amount of folate is needed for cells under rapid proliferation such as cancer cells. Folate receptors (FRs) are shown to be overexpressed on the surface of tumor cells under low folate conditions and viewed as tumor-associated antigen. The FRs could specifically bind folate and folate conjugates with very high affinity and then transport ...
Weidong Yang, Cheng Wang, Gang Huang
openaire +1 more source
Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?
European Journal of Nuclear Medicine and Molecular Imaging, 2015The end point vision of efficacy has changed over recent years [28]. Improved quality of life and keeping a good quality of life plays a central role in the treatment algorithm of the NET patient. Substantial toxicity rates are associated with the use of novel targeted therapies such as the mTOR inhibitors and tyrosine kinase inhibitors. In contrast to
openaire +2 more sources